Exelixis’ experimental drug zanzalintinib combined with Roche’s checkpoint inhibitor Tecentriq demonstrated a significant overall survival improvement versus Bayer’s Stivarga in a pivotal Phase 3 metastatic colorectal cancer study. The combination reduced the risk of death, positioning zanzalintinib as a promising successor to Cabometyx with substantial commercial potential. Following the positive topline data release, Exelixis shares surged, reflecting investor confidence in the drug’s clinical and market prospects.